Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Heart transplant allocation policy changes in 2016 and 2018 improved waitlist outcomes for children born with heart defects but not adults. The changes benefited adults with cardiomyopathy but not ...